Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer - Stopeck, Alison T.; Fizazi, Karim; Body, Jean-Jacques; Brown, Janet E.; Carducci, Michael; Diel, Ingo; Fujiwara, Yasuhiro; Martín, Miguel; Paterson, Alexander; Tonkin, Katia; Shore, Neal; Sieber, Paul; et al. (Supportive care in cancer, 2016)
Keywords: Administration, Cutaneous; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - adverse effects; Bone Neoplasms - drug therapy; Bone Neoplasms - secondary; Breast cancer; Breast Neoplasms; Cancer metastasis; Cancer research; Cancer therapies; Care and treatment; Clinical trials; Denosumab - administration & dosage; Denosumab - adverse effects; Diphosphonates - administration & dosage; Diphosphonates - adverse effects; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles - administration & dosage; Imidazoles - adverse effects; Infusions, Intravenous; Long-Term Care; Male; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Nursing; Nursing Research; Oncology; Original; Original Article; Pain Medicine; Prostate cancer; Prostatic Neoplasms; Rehabilitation Medicine; Safety and security measures; Treatment Outcome; Zoledronic Acid; Zoledronic acid; Breast cancer; Denosumab; Prostate cancer; Osteonecrosis of the jaw; Bone metastases